Market Place
Sourcing Support
Astellas pays $50M for option on AviadoBio dementia gene therapy
08 Oct 2024 //
FIERCE BIOTECH
ASPIRE-FTD Phase 1/2 Trial Opens At Ohio State Wexner Medical Center
01 Jul 2024 //
BUSINESSWIRE
AviadoBio Doses First AVB-101 Frontotemporal Dementia Patient
15 Apr 2024 //
BUSINESSWIRE
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101
06 Nov 2023 //
BUSINESSWIRE
AviadoBio Announces Presentation of Safety and Biodistribution Data of AVB-101
24 Oct 2023 //
BUSINESSWIRE
AviadoBio Announces Initiation of Phase 1/2 Evaluating AVB-101
10 Oct 2023 //
BUSINESSWIRE
AviadoBio Signs Exclusive License Agreement with Neurgain Technologies
23 Feb 2023 //
BUSINESSWIRE
AviadoBio Announces Appointment of Jeff Goater as Chair of Board of Directors
01 Feb 2023 //
BUSINESSWIRE
AviadoBio Appoints Graeme Fielder as Chief Operating Officer
04 Oct 2022 //
GLOBENEWSWIRE
AviadoBio Appoints Dr. David Cooper as Chief Medical Officer
02 Aug 2022 //
GLOBENEWSWIRE
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101
17 May 2022 //
GLOBENEWSWIRE
AviadoBio Announces Formation of Scientific Advisory Board Â
12 May 2022 //
GLOBENEWSWIRE
AviadoBio Announces Formation of Scientific Advisory Board
12 May 2022 //
GLOBENEWSWIRE
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate
04 May 2022 //
GLOBENEWSWIRE
FDA grants ODD for frontotemporal dementia therapy
28 Apr 2022 //
HEALIO
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.